Wushuang Medical Secures RMB 150 Million in Series C Funding to Advance Cardiac Rhythm Management Innovations

Mar 12, 2025 17:18 CST Updated 17:18

Singular Medical

Developer, Manufacturer, and Seller of Cardiac Rhythm Management Products

Call for Partners: 2025 Global Surgical Robotics Conference

Registration: First Global Ophthalmology Conference | Tentative Agenda

Registration: First Global Cardiovascular Conference | Award Registration Countdown

Registration: The First Global Orthopedic Conference | Award Registration Countdown

March 12, 2025,Singular Medical(hereinafter referred to as "Singular Medical") announcedCompleted nearly 150 million RMB in Series C financing. This round of financing was led byTasly CapitalLed by, existing shareholdersQiming Venture Partners, SND Finance, Kangyu CapitalContinue to support. The financing funds will be mainly used for the company's new generation product research and development and commercialization., further solidifying its leading position in the industry.

# Company Introduction

Singular MedicalFounded on July 11, 2017, with its headquarters located in the Suzhou New District Medical Device Park. The company is focused onCardiac Rhythm Management (CRM)Hard-tech enterprises related to the research, development, and industrialization of medical devices. Singular Medical is committed to building a high-end CRM medical device brand in China, with a product line coveringImplantable Cardioverter Defibrillator (ICD), Implantable Cardiac Monitor (ICM), and Implantable Pacemakeretc.

Core Products and Technologies

Singular Medical - Ambu^®ICD：The product began clinical trials at the end of 2023, has completed all patient enrollment and follow-up, and has successfully treated more than ten patients with ventricular arrhythmia outside the hospital. The product has full independent intellectual property rights, and its performance rivals mainstream imported products.
Singular Medical - Si lv^®ICM: Similarly, clinical trials were conducted at the end of 2023. All participants have been enrolled and followed up, demonstrating excellent clinical performance. The product is equipped with Bluetooth telemetry, supporting real-time cloud transmission via mobile phones, covering home monitoring.
Technology Platform: The company started with the ICD, which has the highest technical difficulty in the CRM field,Built a complete CRM technology platform, providing a complete set of solutions for patients with arrhythmia from monitoring, diagnosis, and treatment to postoperative follow-up.

Financing History

Angel Round:Completed angel round financing in 2017, with investors including Northern Light Venture Capital, etc.

Series A:Completed Series A financing in 2020, with investors including Qiming Venture Partners. The funds were used to accelerate the research and development and clinical trials of core products.

Series B:Completed Series B financing in 2022, with investors including SND Holdings and Canrich Capital. The funds will be used to expand the R&D team and advance product clinical trials.

Series C:March 2025Completed nearly 150 million yuan in Series C financingLed by Tasly Capital, with continued support from Qiming Venture Partners, SND Financial Holdings, and CanU Capital, the funds will be used for the research and development of next-generation products and commercialization.